Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,271 · see citing works

Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

Cunningham, D., Allum, W., Stenning, S. P., Thompson, J. N., van de Velde, C. J. �., Nicolson, M. C., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,341 · see citing works

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24 · Cited by 4,519 · see citing works

Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction

Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010187 · Cited by 3,470 · see citing works

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

Bang, Y., Kim, Y., Yang, H., Chung, H. C., Park, Y. K., Lee, K. H., Lee, K., Kim, Y. H., Noh, S.-I., Choi, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61873-4 · Cited by 1,712 · see citing works

Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer

Sasako, M., Sakuramoto, S., Katai, H., Kinoshitá, T., Furukawa, H., Yamaguchi, T., Nashimoto, A., Fujii, M., Nakajima, T., & Ohashi, Y. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5908 · Cited by 1,439 · see citing works

Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B. M., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6 · Cited by 1,088 · see citing works

Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer

gastric (2010) · JAMA · doi:10.1001/jama.2010.534 · Cited by 797 · see citing works

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713 · see citing works

The validation of surrogate endpoints in meta-analyses of randomized experiments

Buyse, M. E., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000) · Biostatistics · doi:10.1093/biostatistics/1.1.49 · Cited by 628 · see citing works

CHEMORADIOTHERAPY AFTER SURGERY COMPARED WITH SURGERY ALONE FOR ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION

Acdonald, J. O. S. M., Malley, R., Acqueline, J., Undahl, S. C. A. H., Orman, N., Stes, C. E., Temmermann, G. R. N. S., Aller, D. A. G. H., Affer, J., Jani, A., et al. (2012) · Cited by 402 · see citing works

Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer

Burzykowski, T., Buyse, M. E., Piccart, M. J., Sledge, G. W., Carmichael, J., Lück, H., Mackey, J. R., Nabholtz, J., Paridaens, R., Biganzoli, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8407 · Cited by 348 · see citing works

The Evaluation of Surrogate Endpoints

Loughin, T. M., Buckl, S. T., Anderson, D. R., Burnham, K. P., Laake, J. L., Borchers, D. L., Thomas, L., Alpizar-jara, R., Fortin, M. J., Shanbhag, D. N., et al. (2005) · Statistics in the health sciences · doi:10.1007/b138566 · Cited by 312 · see citing works

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

Mauguen, A., Pignon, J., Burdett, S., Domerg, C., Fisher, D. J., Paulus, R., Mandrekar, S. J., Belani, C. P., Shepherd, F. A., Eisen, T. G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70158-x · Cited by 245 · see citing works

Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points

Burzykowski, T., Molenberghs, G., Buyse, M. E., Geys, H., & Renard, D. (2001) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.1111/1467-9876.00244 · Cited by 218 · see citing works

Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation

Burzykowski, T., & Buyse, M. E. (2006) · Pharmaceutical Statistics · doi:10.1002/pst.207 · Cited by 206 · see citing works

Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial

Nakajima, T., Nashimoto, A., Kitamura, M., Kito, T., Iwanaga, T., Okabayashi, K., Sasaki, M., & Goto, M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01048-x · Cited by 165 · see citing works

Randomized Trial of Adjuvant Chemotherapy With Mitomycin, Fluorouracil, and Cytosine Arabinoside Followed by Oral Fluorouracil in Serosa-Negative Gastric Cancer: Japan Clinical Oncology Group 9206–1

Nashimoto, A., Nakajima, T., Furukawa, H., Kitamura, M., Kinoshitá, T., Yamamura, Y., Sasako, M., Kunii, Y., Motohashi, H., & Yamamoto, S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.103 · Cited by 164 · see citing works

Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis

a (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.016 · Cited by 161 · see citing works

A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.

Coombes, R. C., Schein, P. S., Chilvers, C. E. D., Wils, J. A., Beretta, G. D., Bliss, J. M., Rutten, A., Amadori, D., Cortés-Funes, H., & Grimalt, A. V. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.8.1362 · Cited by 154 · see citing works

Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801)

Bouché, O., Ychou, M., Burtin, P. C., Bedenne, L., Ducreux, M. P., Lebreton, G., Baulieux, J., Nordlinger, B., Martin, C., Seitz, J., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi270 · Cited by 150 · see citing works

Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group

Bajetta, E., Buzzoni, R., Mariani, L., Beretta, E., Bozzetti, F., Bordogna, G., Aitini, E., Fava, S., Schieppati, G., Pinotti, G., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf040 · Cited by 138 · see citing works

Randomized controlled trial of adjuvant uracil–tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer

Nakajima, T., Kinoshitá, T., Nashimoto, A., Sairenji, M., Yamaguchi, T., Sakamoto, J., Fujiya, T., Inada, T., Sasako, M., & Ohashi, Y. (2007) · British journal of surgery · doi:10.1002/bjs.5996 · Cited by 134 · see citing works

Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC

Costanzo, F. D., Gasperoni, S., Manzione, L., Bisagni, G., Labianca, R., Bravi, S., Cortesi, E., Carlini, P., Bracci, R., Tomao, F., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn054 · Cited by 127 · see citing works

Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A southwest oncology group study

Macdonald, J. S., Fleming, T. R., Peterson, R. F., Berenberg, J. L., McClure, S., Chapman, R., Eyre, H. J., Solanki, D. L., Cruz, A. B., Gagliano, R. G., et al. (1995) · Annals of Surgical Oncology · doi:10.1007/bf02307081 · Cited by 123 · see citing works

Randomized Clinical Trial of Adjuvant Mitomycin Plus Tegafur in Patients With Resected Stage III Gastric Cancer

Cirera, L., Balil, A., Batiste-Alentorn, E., Tusquets, I., Cardona, T., Arcusa, À., Jolis, L., Saigí, E., Guasch, I., Badia, A. C., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3810 · Cited by 115 · see citing works

Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.

Lise, M., Nitti, D., Marchet, A., Sahmoud, T., Buyse, M. E., Duez, N. J., Fiorentino, M. V., Santos, J. G. D., Labianca, R., & Rougier, P. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2757 · Cited by 108 · see citing works

Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)

Vita, F. D., Giuliani, F., Orditura, M., Maiello, E., Galizia, G., Martino, N. D., Montemurro, F., Cartenì, G., Manzione, L., Romito, S., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm128 · Cited by 103 · see citing works

Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG

Nitti, D., Wils, J., dos Santos, J. G., Fountzilas, G., Conte, P., Sava, C., Tres, A., Coombes, R. C., Crivellari, D., Marchet, A., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj077 · Cited by 92 · see citing works

Individual- and trial-level surrogacy in colorectal cancer

Buyse, M. E., Burzykowski, T., Michiels, S., & Carroll, K. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207081864 · Cited by 84 · see citing works

Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: A phase III trial by the eastern cooperative oncology group (EST: 4275)

Engstrom, P. F., Macintyre, J. M., Douglass, H. O., Muggia, F. M., & Mittelman, A. (1982) · Cancer · doi:10.1002/1097-0142(19820415)49:8 · Cited by 29 · see citing works

Estimate of breast cancer risk reduction with weight loss

Schapira, D. V., Kumar, N. B., & Lyman, G. H. (1991) · Cancer · doi:10.1002/1097-0142(19910515)67:10 · Cited by 23 · see citing works

5-Fluorouracil, Epirubicin, and Mitomycin C Versus 5-Fluorouracil, Epirubicin, Mitomycin C, and Leucovorin in Advanced Gastric Carcinoma

Tsavaris, N. B., Tentas, K., Kosmidis, P., Mylonakis, N., Sakelaropoulos, N., Kosmas, C., Lisaios, B., Soumilas, A., Mandrekois, D., Tsetis, A., et al. (1996) · American Journal of Clinical Oncology · doi:10.1097/00000421-199610000-00018 · Cited by 9 · see citing works

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Kelly, R. J., Ajani, J. A., Kużdżał, J., Zander, T., Cutsem, E. V., Piessen, G., Mendez, G. A., Feliciano, J. L., Motoyama, S., Lièvre, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032125 · Cited by 1,863 · see citing works

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · see citing works

The Strength of Association Between Surrogate End Points and Survival in Oncology

Prasad, V. K., Kim, C., Burotto, M., & Vandross, A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.2829 · Cited by 417 · see citing works

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

Yoshida, K., Kodera, Y., Kochi, M., Ichikawa, W., Kakeji, Y., Sano, T., Nagao, N., Takahashi, M., Takagane, A., Watanabe, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01138 · Cited by 394 · see citing works

Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912

Katai, H., Mizusawa, J., Katayama, H. G., Takagi, M., Yoshikawa, T., Fukagawa, T., Terashima, M., Misawa, K., Teshima, S., Koeda, K., et al. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0646-9 · Cited by 388 · see citing works

Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial

Katai, H., Mizusawa, J., Katayama, H. G., Morita, S., Yamada, T., Bando, E., Ito, S., Takagi, M., Takagane, A., Teshima, S., et al. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30332-2 · Cited by 332 · see citing works

Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer

Huang, C., Liu, H., Hu, Y., Sun, Y., Su, X., Cao, H., Hu, J.-K., Wang, K., Suo, J., Tao, K., et al. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2021.5104 · Cited by 286 · see citing works

A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology

Haslam, A., Hey, S. P., Gill, J., & Prasad, V. K. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.012 · Cited by 209 · see citing works

Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials

Mushti, S. L., Mulkey, F. A., & Sridhara, R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1902 · Cited by 162 · see citing works

Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer

Son, S., Hur, H., Hyung, W. J., Park, Y., Lee, H.-J., An, J. Y., Kim, W., Kim, H., Kim, H., Ryu, S. W., et al. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2022.2749 · Cited by 148 · see citing works

Statistical evaluation of surrogate endpoints with examples from cancer clinical trials

Buyse, M. E., Molenberghs, G., Paolettí, X., Oba, K., Alonso, A., der Elst, W. V., & Burzykowski, T. (2015) · Biometrical Journal · doi:10.1002/bimj.201400049 · Cited by 140 · see citing works

A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed

Wang, S., Liu, Y., Feng, Y., Zhang, J., Swinnen, J. V., Li, Y., & Ni, Y. (2019) · Cancers · doi:10.3390/cancers11111782 · Cited by 121 · see citing works

Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial

Tsuburaya, A., Yoshida, K., Kobayashi, M., Yoshino, S., Takahashi, M., Takiguchi, N., Tanabe, K., Takahashi, N., Imamura, H., Tatsumoto, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70025-7 · Cited by 109 · see citing works

Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Kang, Y., Terashima, M., Kim, Y., Boku, N., Chung, H. C., Chen, J., Ji, J., Yeh, T., Chen, L., Ryu, M., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00156-0 · Cited by 104 · see citing works

Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07

Kakeji, Y., Yoshida, K., Kodera, Y., Kochi, M., Sano, T., Ichikawa, W., Lee, S., SHIBAHARA, K., Shikano, T., Kataoka, M., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01224-2 · Cited by 93 · see citing works

Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis

Rotolo, F., Pignon, J., Bourhis, J., Marguet, S., Leclercq, J., Ng, W. T., Ma, J., Chan, A. T. �., Huang, P., Zhu, G., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw239 · Cited by 86 · see citing works

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis

Mulkey, F. A., Theoret, M. R., Keegan, P., Pazdur, R., & Sridhara, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000146 · Cited by 80 · see citing works

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis

Saad, E. D., Squifflet, P., Burzykowski, T., Quinaux, E., Delaloge, S., Mavroudis, D., Perez, E. A., Piccart, M. J., Schneider, B. P., Slamon, D. J., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30750-2 · Cited by 80 · see citing works

Surrogacy Beyond Prognosis: The Importance of “Trial-Level” Surrogacy

Buyse, M. E., Saad, E. D., Burzykowski, T., Regan, M. M., & Sweeney, C. J. (2022) · The Oncologist · doi:10.1093/oncolo/oyac006 · Cited by 67 · see citing works

Personalized dynamic prediction of death according to tumour progression and high-dimensional genetic factors: Meta-analysis with a joint model

Emura, T., Nakatochi, M., Matsui, S., Michimae, H., & Rondeau, V. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280216688032 · Cited by 65 · see citing works

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy

Squifflet, P., Saad, E. D., Loibl, S., van Mackelenbergh, M., Untch, M., Rastogi, P., Gianni, L., Schneeweiß, A., Conte, P., Piccart, M. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02363 · Cited by 61 · see citing works

Preoperative apolipoprotein B/apolipoprotein A1 ratio: a novel prognostic factor for gastric cancer

Ma, M.-Z., Yuan, S., Chen, Y.-M., & Zhou, Z.-W. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s156690 · Cited by 62 · see citing works

Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis

Galizia, G., Lieto, E., Vita, F. D., Castellano, P., Ferraraccio, F., Zamboli, A. G. I., Mabilia, A., AURICCHIO, A., Sena, G. D., Stefano, L. D., et al. (2014) · Surgery · doi:10.1016/j.surg.2014.09.012 · Cited by 61 · see citing works

Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY

Kang, Y., Kim, H., Yook, J. H., Park, Y., Lee, J. S., Kim, Y., Kim, J. Y., Ryu, M., Rha, S. Y., Chung, I., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02167 · Cited by 59 · see citing works

Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis

Kanda, M., Murotani, K., Kobayashi, D., Tanaka, C., Yamada, S., Fujii, T., Nakayama, G., Sugimoto, H., Koike, M., Fujiwara, M., et al. (2015) · Surgery · doi:10.1016/j.surg.2015.05.017 · Cited by 56 · see citing works

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

Michiels, S., Pugliano, L., Marguet, S., Grun, D., Barinoff, J., Cameron, D., Cobleigh, M., Leo, A. D., Johnston, S. R. D., Gasparini, G. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw132 · Cited by 52 · see citing works

Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer

Bartolomeo, M. D., Pietrantonio, F., Pellegrinelli, A., Martinetti, A., Mariani, L., Daidone, M. G., Bajetta, E., Pelosi, G., de Braud, F., Floriani, I., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0495-y · Cited by 51 · see citing works

Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review

Savina, M., Gourgou, S., Italiano, A., Dinart, D., Rondeau, V., Penel, N., Mathoulin‐Pélissier, S., & Bellera, C. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.014 · Cited by 51 · see citing works

New Findings on Presentation and Outcome of Patients With Adrenocortical Cancer: Results From a National Cohort Study

Puglisi, S., Calabrese, A., Ferraù, F., Violi, M. A., Laganà, M., Grisanti, S., Ceccato, F., Scaroni, C. M., Dalmazi, G. D., Stigliano, A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad199 · Cited by 44 · see citing works

Survival and overall treatment time after postoperative radio(chemo)therapy in patients with head and neck cancer

Tribius, S., Donner, J., Pazdyka, H., Münscher, A., Gröbe, A., Petersen, C., Krüll, A., & Tennstedt, P. (2016) · Head & Neck · doi:10.1002/hed.24407 · Cited by 44 · see citing works

Primary Pulmonary Carcinoid Tumor

Herde, R. F., Kokeny, K. E., Reddy, C. B., Akerley, W., Hu, N., Boltax, J., & Hitchcock, Y. J. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000221 · Cited by 44 · see citing works

An individualized prognostic signature and multi-omics distinction for early stage hepatocellular carcinoma patients with surgical resection

Ao, L., Song, X., Li, X., Tong, M., Guo, Y., Li, J., Li, H., Cai, H., Li, M., Guan, Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8212 · Cited by 41 · see citing works

MicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential

Matuszcak, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i38.13658 · Cited by 40 · see citing works

Conditional copula models for correlated survival endpoints: Individual patient data meta-analysis of randomized controlled trials

Emura, T., Sofeu, C. L., & Rondeau, V. (2021) · Statistical Methods in Medical Research · doi:10.1177/09622802211046390 · Cited by 39 · see citing works

Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis

Ajani, J. A., Leung, L., Singh, P., Kurt, M., Kim, I., Pourrahmat, M., & Kanters, S. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.027 · Cited by 38 · see citing works

Lymphadenectomy extent and survival of patients with gastric carcinoma: A systematic review and meta-analysis of time-to-event data from randomized trials

D, S. M. M., & Nitti, D. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.003 · Cited by 37 · see citing works

Low expression of RBMS3 and SFRP1 are associated with poor prognosis in patients with gastric cancer.

Zhang, T., Wu, Y., Fang, Z., Yan, Q., Zhang, S., Sun, R., Khaliq, J., & Li, Y. (2016) · PubMed Central · Cited by 37 · see citing works

Randomized controlled Phase III trial to evaluate omentum preserving gastrectomy for patients with advanced gastric cancer (JCOG1711, ROAD-GC)

Sato, Y., Yamada, T., Yoshikawa, T., Machida, R., Mizusawa, J., Katayama, H. G., Tokunaga, M., Boku, N., & Terashima, M. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa113 · Cited by 37 · see citing works

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses

Norsworthy, K. J., Gao, X., Ko, C., Pulte, D. D., Zhou, J., Gong, Y. U. T., Shen, Y. L., Vallejo, J. J., Gwise, T. E., Sridhara, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01548 · Cited by 37 · see citing works

Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges

Miceli, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i16.4516 · Cited by 36 · see citing works

surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials

Rotolo, F., Paolettí, X., & Michiels, S. (2017) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2017.12.005 · Cited by 36 · see citing works

Targeted therapy in gastric cancer

Jomrich, G., & SCHOPPMANN, S. F. (2016) · European surgery. Supplement/European surgery · doi:10.1007/s10353-016-0389-1 · Cited by 35 · see citing works

Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers

Petrelli, F., Tomasello, G., & Barni, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.032 · Cited by 35 · see citing works

Raising the bar for using surrogate endpoints in drug regulation and health technology assessment

Dawoud, D., Naci, H., Ciani, O., & Bujkiewicz, S. (2021) · BMJ · doi:10.1136/bmj.n2191 · Cited by 34 · see citing works

Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal Cancer: A Systematic Review and Meta-analysis

Su, F., Yang, X., Yin, J., Shen, Y., & Tan, L. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13778-9 · Cited by 33 · see citing works

Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy

Fujitani, K., Tamura, S., Kimura, Y., Tsuji, T., Matsuyama, J., Iijima, S., Imamura, H., Inoue, K., Kobayashi, K., Kurokawa, Y., et al. (2013) · Gastric Cancer · doi:10.1007/s10120-013-0273-7 · Cited by 32 · see citing works

Evaluation of the Association of Perioperative UGT1A1 Genotype–Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma

Catenacci, D. V. T., Chase, L. M., Lomnicki, S., Karrison, T. G., Marsh, R., Rampurwala, M. M., Narula, S., Alpert, L., Setia, N., Xiao, S., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.21290 · Cited by 32 · see citing works

Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials

Chen, Y., Sun, Y. H., Chen, L., Mao, Y., Tang, L., Li, W., Liu, X., Zhang, W.-N., Zhou, G., Guo, R., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.07.030 · Cited by 31 · see citing works

Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints

Bujkiewicz, S., Thompson, J. R., Spata, E., & Abrams, K. R. (2015) · Statistical Methods in Medical Research · doi:10.1177/0962280215597260 · Cited by 28 · see citing works

Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance

Wang, H., Lu, Y., Wang, M., Wu, Y., Wang, X., & Li, Y. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02015-5 · Cited by 26 · see citing works

Intraperitoneal Chemotherapy as Adjuvant or Perioperative Chemotherapy for Patients with Type 4 Scirrhous Gastric Cancer: PHOENIX-GC2 Trial

Ishigami, H., Tsuji, Y., Shinohara, H., Kodera, Y., Kanda, M., Yabusaki, H., Ito, S., Imano, M., Yamashita, H., Hidemura, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235666 · Cited by 25 · see citing works

Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials

Nie, R., Chen, F., Provencio, M., Wang, Y., van den Ende, T., van Laarhoven, H. W. M., Yuan, S., Pless, M., Hayoz, S., Zhou, Z., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.010 · Cited by 25 · see citing works

An improved method for bivariate meta‐analysis when within‐study correlations are unknown

Hong, C., Riley, R. D., & Chen, Y. (2017) · Research Synthesis Methods · doi:10.1002/jrsm.1274 · Cited by 25 · see citing works

Elevated TRIM23 expression predicts poor prognosis in Chinese gastric cancer

Yao, Y., Liu, Z., Guo, H., Huang, S., Zhong, M., Deng, J., & Xiong, J. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.10.010 · Cited by 25 · see citing works

Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer

Hwang, J., Kim, H.-J., Shim, H., Bae, W., Hwang, E. C., Jeong, O., Ryu, S. Y., Park, Y. K., Cho, S., & Chung, I. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02963-7 · Cited by 22 · see citing works

Assessment of Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature

Lin, J., Lin, J.-P., Wang, Z., Li, P., Xie, J., Wang, J.-B., Lü, J., Chen, Q., Cao, L., Lin, M., et al. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2022.5307 · Cited by 22 · see citing works

Identification of novel prognostic biomarkers by integrating multi-omics data in gastric cancer

Liu, N., Wu, Y., Cheng, W., Wu, Y., Wang, L., & Zhuang, L. (2021) · BMC Cancer · doi:10.1186/s12885-021-08210-y · Cited by 22 · see citing works

Cowden Syndrome and the PTEN Hamartoma Tumor Syndrome: How to Define Rare Genetic Syndromes

Lachlan, K. L. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt290 · Cited by 22 · see citing works

A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses

Rotolo, F., Paolettí, X., Burzykowski, T., Buyse, M. E., & Michiels, S. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280217718582 · Cited by 21 · see citing works

EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas

Petrini, I., Lencioni, M., Vasile, E., Fornaro, L., Belluomini, L., Pasquini, G., Ginocchi, L., Caparello, C., Musettini, G., Vivaldi, C., et al. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170865 · Cited by 21 · see citing works

Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience

Galizia, G., Lieto, E., AURICCHIO, A., Cardella, F., Mabilia, A., Diana, A., Castellano, P., Vita, F. D., & Orditura, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173619 · Cited by 21 · see citing works

Potential of Bioactive Food Components against Gastric Cancer: Insights into Molecular Mechanism and Therapeutic Targets

Kang, S. Y., Hwang, D., Shin, S., Park, J., Kim, M., Rahman, M. H., Rahman, M. A., Ko, S., & Kim, B. (2021) · Cancers · doi:10.3390/cancers13184502 · Cited by 20 · see citing works

Elevated HABP1 protein expression correlates with progression and poor survival in patients with gastric cancer

Gao, H., Yao, Q., Lan, X., Li, S., Wu, J., Zeng, G., & Xue, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s114756 · Cited by 20 · see citing works

Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials

Ronellenfitsch, U., Jensen, K., Seide, S., Kieser, M., Schwarzbach, M., Slanger, T. E., Burmeister, B. H., Kelsen, D. P., Niedzwiecki, D., Piessen, G., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.001 · Cited by 20 · see citing works

Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis

Kataoka, K., Nakamura, K., Mizusawa, J., Kato, K., Eba, J., Katayama, H., Shibata, T., & Fukuda, H. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.06.017 · Cited by 20 · see citing works

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial

Lee, C., Jung, M., Kim, H. S., Jung, I., Shin, D. B., Kang, S. Y., Zang, D. Y., Kim, K. H., Lee, M. H., Kim, B. S., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.028 · Cited by 19 · see citing works

Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques

Vandenberghe, S., Duchateau, L., Slaets, L., Bogaerts, J., & Vansteelandt, S. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280217702179 · Cited by 19 · see citing works

Explainable machine learning via intra-tumoral radiomics feature mapping for patient stratification in adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma

Teng, X., Zhang, J., Han, X., Sun, J., Lam, S., Ai, Q. Y. H., Ma, Z., Lee, F. K.-H., Au, K., Yip, C. W.-Y., et al. (2023) · La radiologia medica · doi:10.1007/s11547-023-01650-5 · Cited by 18 · see citing works

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials

Nie, R., Zou, X., Yuan, S., Chen, Y.-B., Chen, S., Chen, Y.-M., Chen, G., Chen, X., Luo, T., Li, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06910-5 · Cited by 18 · see citing works

Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis

Untch, M., Pérol, D., Mayer, E. L., Cortés, J., Nusch, A., Cameron, D., Barrios, C. H., Delea, T. E., Danyliv, A., Mishra, N., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113977 · Cited by 17 · see citing works

The value of serum RASSF10 hypermethylation as a diagnostic and prognostic tool for gastric cancer

Xue, W., Feng, Y., Wang, F., Li, P., Liu, Y., Guo, Y., Wang, Z., & Mao, Q.-S. (2016) · Tumor Biology · doi:10.1007/s13277-016-5001-6 · Cited by 17 · see citing works

Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta‐analysis of randomized controlled trials

Laporte, S., Chapelle, C., Bertoletti, L., Ollier, É., Zufferey, P. J., Lega, J., Merah, A., Decousus, H., Schulman, S., Meyer, G., et al. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13740 · Cited by 17 · see citing works

Preoperative versus Post-operative Radiotherapy for Extremity Soft tissue Sarcoma: a Systematic Review and Meta-analysis of Long-term Survival

Kungwengwe, G., Clancy, R. M., Vass, J., Slade, R. R., Sandhar, S., Dobbs, T. D., & Bragg, T. W. H. (2021) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2021.05.043 · Cited by 17 · see citing works

Adjuvant therapy for gastric cancer: What have we learned since INT0116?

Jacome, A. A. D. A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i13.3850 · Cited by 17 · see citing works

Significant association of YAP1 and HSPC111 proteins with poor prognosis in Chinese gastric cancer patients

Huang, S., Zhu, L., Cao, Y., Li, L., Xie, Y., Deng, J., & Xiong, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17932 · Cited by 16 · see citing works

Survival Outcomes of Hepatectomy in Gastric Cancer Liver Metastasis: A Systematic Review and Meta-Analysis

Conde, D., Ibáñez‐Pinilla, M., Sabogal, J. C., Cháves, C. E. R., Isaza-Restrepo, A., Girón, F., Vanegas, M., Ibañez-Villalba, R., Mirow, L., & Siepmann, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020704 · Cited by 16 · see citing works

Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer

Siddiqui, M. K., Tyczynski, J. E., Pahwa, A., & Fernandes, A. W. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.03.515 · Cited by 16 · see citing works

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report

Hardenberg, M. C., Patel, B., Matthews, C., Califano, R., Campelo, R. G., Grohé, C., Hong, M. H., Liu, G., Lü, S., de Marinis, F., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100572 · Cited by 15 · see citing works

Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan

Maeda, H., Shingai, R., Takeda, K., Hara, A., Murai, Y., & Ofuchi, M. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.8875 · Cited by 15 · see citing works

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials

Li, Y., Yuan, S., Chen, Y.-B., Nie, M., Li, J., Chen, G., Chen, X., Zhang, R., Zheng, Z., Wei, C., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad125 · Cited by 15 · see citing works

Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real‐world data

Jongeneel, G., Klausch, T. L. T., van Erning, F. N., Vink, G. R., Koopman, M., Punt, C. J. A., Greuter, M. J. E., & Coupé, V. M. H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32629 · Cited by 15 · see citing works

Identification and Validation of a Novel Pyroptosis-Related Gene Signature for Prognosis Prediction in Soft Tissue Sarcoma

Qi, L., Xu, R., Wan, L., Ren, X., Zhang, W., Zhang, K., Tu, C., & Li, Z. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.773373 · Cited by 14 · see citing works

Low expression of fibulin-1 correlates with unfavorable prognosis in gastric cancer

Feng, L., Yao, C., Li, P., Feng, Y., Wang, F., Liu, Y., Guo, Y., Mao, Q.-S., & Xue, W. (2016) · Tumor Biology · doi:10.1007/s13277-015-4537-1 · Cited by 14 · see citing works

Prognostic and Clinicopathological Significance of SERTAD1 in Various Types of Cancer Risk: A Systematic Review and Retrospective Analysis

Mongre, R. K., Jung, S., Mishra, C. B., Lee, B. S., Kumari, S., & Lee, M. (2019) · Cancers · doi:10.3390/cancers11030337 · Cited by 14 · see citing works

Neoadjuvant and adjuvant end-points in health technology assessment in oncology

Harbeck, N., Schneeweiß, A., Thuss-Patience, P. C., Miller, K., Garbe, C., Griesinger, F., Eberhardt, W., Klußmann, J. P., Wollenberg, B., Grimm, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.006 · Cited by 14 · see citing works

Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma

Okui, J., Nagashima, K., Matsuda, S., Sato, Y., Okamura, A., Kawakubo, H., Muto, M., Kakeji, Y., Kono, K., Takeuchi, H., et al. (2024) · British journal of surgery · doi:10.1093/bjs/znae038 · Cited by 13 · see citing works

Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study

Endo, S., Terazawa, T., Goto, M., Tanaka, R., Kato, T., Fujitani, K., Kawakami, H., Sakai, D., Kurokawa, Y., Tsujinaka, T., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09890-w · Cited by 12 · see citing works

Potential role of TET2 in gastric cancer cisplatin resistance

Zhou, K., Guo, H., Zhang, J., Zhao, D., Zhou, Y., Zheng, Z., Xu, Y., Li, Y., & Wang, D. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152637 · Cited by 12 · see citing works

Multiple event times in the presence of informative censoring: modeling and analysis by copulas

Li, D., Hu, X. J., McBride, M. L., & Spinelli, J. J. (2019) · Lifetime Data Analysis · doi:10.1007/s10985-019-09490-0 · Cited by 12 · see citing works

A Meta-Analysis for Simultaneously Estimating Individual Means with Shrinkage, Isotonic Regression and Pretests

Taketomi, N., Konno, Y., Chang, Y.-T., & Emura, T. (2021) · Axioms · doi:10.3390/axioms10040267 · Cited by 12 · see citing works

One‐step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure‐time endpoints

Sofeu, C. L., Emura, T., & Rondeau, V. (2019) · Statistics in Medicine · doi:10.1002/sim.8162 · Cited by 12 · see citing works

The treatment of resectable gastric cancer: a literature review of an evolving landscape

Tung, I., & Sahu, A. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-721 · Cited by 10 · see citing works

Improving prognosis after surgery for gastric cancer

Nishida, T., & Doi, T. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71019-8 · Cited by 11 · see citing works

Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints

Saad, E. D., & Buyse, M. E. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000636 · Cited by 11 · see citing works

Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting

Wainberg, Z. A., Xie, J., Valderrama, A., Yin, L., Zhang, S., Shih, C., Bhagia, P., Gu, Q., Shitara, K., Janjigian, Y. Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2920 · Cited by 10 · see citing works

Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials

Petrelli, F., Tomasello, G., Ghidini, M., Lonati, V., Passalacqua, R., & Barni, S. (2017) · HPB · doi:10.1016/j.hpb.2017.07.005 · Cited by 10 · see citing works

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma

Liu, H., Wang, Y., Qi, C., Xie, T., Peng, Z., Li, J., Shen, L., & Zhang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.835389 · Cited by 9 · see citing works

A Comparison of the Performance of 6 Surrogacy Models, Including Weighted Linear Regression, Meta-Regression, and Bivariate Meta-Analysis

Vickers, A. D. (2025) · Value in Health · doi:10.1016/j.jval.2025.01.005 · Cited by 9 · see citing works

Minimally invasive surgery in advanced gastric cancer

Lee, S. J., & Kim, H. (2022) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12559 · Cited by 9 · see citing works

Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002)

the Osaka Gastrointestinal Cancer Chemotherapy Study Group, Fujitani, K., Tamura, S., Kimura, Y., Matsuyama, J., Imamura, H., Yamamoto, K., Fujita, J., Iijima, S., Ueda, S., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-019-01023-w · Cited by 8 · see citing works

Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-analysis

Burzykowski, T., Bang, Y., & on behalf of the GASTRIC project (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4517 · Cited by 11 · see citing works

Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials

Ronellenfitsch, U., Jensen, K., Seide, S., Kieser, M., Schwarzbach, M., Slanger, T. E., Burmeister, B. H., Kelsen, D. P., Niedzwiecki, D., Piessen, G., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.001 · Cited by 20 · see citing works

Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomized controlled trials.

Ronellenfitsch, U., Jensen, K., Seide, S., Kieser, M., Schwarzbach, M., Slanger, T. E., Burmeister, B. H., Kelsen, D. P., Niedzwiecki, D., Piessen, G., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4533 · Cited by 1 · see citing works

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma

Liu, H., Wang, Y., Qi, C., Xie, T., Peng, Z., Li, J., Shen, L., & Zhang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.835389 · Cited by 9 · see citing works

Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis

Paolettí, X., Oba, K., Bang, Y., Bleiberg, H., Boku, N., Bouché, O., Catalano, P. J., Fuse, N., Michiels, S., Moehler, M. H., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt269 · Cited by 90 · see citing works